Transdermal selegiline: A new-generation MAOI

Primary Psychiatry

Volumn 13, Issue 5, 2006, Pages 33-35

  Robinson, Donald S ^a  

^a Worldwide Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; CORTICOSTEROID; HYDROCORTISONE; HYPNOTIC AGENT; MONOAMINE OXIDASE INHIBITOR; PENTAZOCINE; PETHIDINE; SELEGILINE; TRANYLCYPROMINE;

CLINICAL TRIAL; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FOOD DRUG INTERACTION; HUMAN; HYPERTENSION; INSOMNIA; MAJOR DEPRESSION; MEDICAL LIABILITY; NERVOUSNESS; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SHORT SURVEY; SIDE EFFECT; SKIN MANIFESTATION; TRANSDERMAL PATCH; WEIGHT GAIN; XEROSTOMIA;

EID: 33646492158     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (10)

1. Robinson DS. Monoamine oxidase inhibitors; a new generation. Psychopharmacol Bull. 2002;36(3):124-138.
2. Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between monoamine inhibitors and foodstuffs. Br J Psychiatry. 1967;113(497):349-365.
3. Azzaro AJ, VanDenBerg CM, Blob LF, et al. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/ 24 hr in healthy subjects. J Clin Pharmacol. In press.
4. Shuiman KI, Walker SE, MacKenzie S, Knowles S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacology. 1989;9(6);397-402.
5. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind placebo-controlled parallel-group study in outpatients. Am J Psychiatry. 2002;159(11):1869-1875.
6. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64(2):208-214.
7. Robinson DS, Moonsammy G, Azzaro AJ. Relapse prevention study shows the long-term safety and efficacy of transdermal selegiline, a new generation MAOI. Poster presented at: the 41st Annual Meeting of the American College of Neuropsychopharmacology; December 11, 2002; San Juan, Puerto Rico.
8. EMSAM [package insert]. New York, NY: Bristol-Myers Squibb; 2006.
9. Shuiman KI, Walker SE. A reevaluation of dietary restrictions for irreversible monoamine oxidase inhibitors. Psychiatr Ann. 2001;31(6):378-384.
10. Robinson DS, Campbell BJ, Amsterdam JD. Safety and tolerability of the selegiline transdermal system 20 mg for treatment of major depressive disorder. Neumpsychopharmacology. 2005;30(suppl 1):S234.